Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?
The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.